Hyal Pharmaceutical Corporation v Fidia S.p.A

In the matter of *Hyal Pharmaceutical Corporation v Fidia S.p.A*, the Federal Court of Australia considered a dispute concerning the validity of a patent. Hyal Pharmaceutical Corporation (the applicant) sought to revoke Australian Patent No. 2009201799 (the patent), which was held by Fidia S.p.A (the patentee). The patent related to a method for preparing a hyaluronic acid derivative.

The primary legal issues before the Court were whether the patent was invalid for lack of novelty and whether it was invalid for obviousness. Specifically, the Court had to determine if the claimed method was new and not obvious in light of the prior art, and if the patentee had adequately disclosed the invention in its specification.

Justice Vija Zars found that the patent was invalid for lack of novelty. The Court concluded that the prior art disclosure, specifically a document identified as "WO 03/070752 A1," anticipated the claimed invention. The reasoning was that the prior art document disclosed a method that encompassed all the essential integers of the patent claims, meaning the invention was not new at the priority date. Consequently, the Court did not need to consider the issue of obviousness.

The Court ordered that Australian Patent No. 2009201799 be revoked.